Featured Research

from universities, journals, and other organizations

New Single-Dose Orthopoxvirus Drug In First Stage Of Human Trials

Date:
May 27, 2008
Source:
American Society for Microbiology
Summary:
A new single-dose antiviral drug has been developed against orthopoxvirus that was safely tolerated in humans during phase I trials and could potentially be used to prevent and treat smallpox. Prior to eradication, variola virus, the causative agent of smallpox and member of the orthopoxvirus family, was estimated to have killed, crippled, or disfigured up to 10% of the human population.

Researchers from SIGA Technologies, TransTech Pharma, and INC Research developed a new single-dose antiviral drug against orthopoxvirus that was safely tolerated in humans during phase I trials and could potentially be used to prevent and treat smallpox.

Prior to eradication, variola virus, the causative agent of smallpox and member of the orthopoxvirus family, was estimated to have killed, crippled, or disfigured up to 10% of the human population. Highly communicable with an exceptionally high morbidity rate, smallpox currently poses a threat as an instrument of biowarfare placing it at the forefront of focus for effective preventative and treatment therapies.

In this phase I study fasting healthy volunteers were administered single oral doses of 500, 1,000, and 2,000 mg of the drug ST-246 and non-fasting healthy volunteers received 1,000 mg. No adverse reactions were observed and no subjects were withdrawn from the study, overall ST-246 was found to be generally well tolerated.

Upon further testing, researchers found absorption to be greater in nonfasting volunteers at a rate of approximately 2 to 3 hours and exposure levels to be sufficient for inhibiting orthopoxvirus replication.

"In conclusion, ST-246 is safe and well tolerated when administered orally as a single dose to healthy human volunteers in a fasting state or non-fasting state," say the researchers.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. Jordan, D. Tien, T.C. Bolken, K.F. Jones, S.R. Tyavanagimatt, J. Strasser, A. Frimm, M.L. Corrado, P.G. Strome, D.E. Hruby. 2008. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrobial Agents and Chemotherapy, 52. 5: 1721-1727. doi:10.1128/AAC.01303-07

Cite This Page:

American Society for Microbiology. "New Single-Dose Orthopoxvirus Drug In First Stage Of Human Trials." ScienceDaily. ScienceDaily, 27 May 2008. <www.sciencedaily.com/releases/2008/05/080523071221.htm>.
American Society for Microbiology. (2008, May 27). New Single-Dose Orthopoxvirus Drug In First Stage Of Human Trials. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2008/05/080523071221.htm
American Society for Microbiology. "New Single-Dose Orthopoxvirus Drug In First Stage Of Human Trials." ScienceDaily. www.sciencedaily.com/releases/2008/05/080523071221.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins